Bayer looking to support local Digital Health projects through its Grants4Apps Programme
Johannesburg, May 12, 2017 – Bayer has announced that applications are now open for its exciting Grant4Apps programme. Geared to connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe, the programme will offer startups an opportunity to become part of an economically inclusive market where innovation is not only encouraged but appreciated as a catalyst for expanding both economic and social growth.
Grants4Apps is an open innovation framework where Bayer aims to collaborate with innovative digital health startups. This platform has been operational for a number of years and since inception, it has borne over three thousand ideas found in approximatly 60 countries. Currently, there are over 10 projects running between Grants4Apps startups and Bayer functions.
“With innovation at the heart of Bayer, we fully appreciate the role that open innovation can play in the healthcare environment. This is particularly important in the African context where the challenges in healthcare differ to the rest of the world. Grants4Apps also represents a unique opportunity for South African innovators to take their work to the next level with the support of Bayer. We are looking for start-ups beyond the ideation phase in developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders,” says Tasniem Patel Head of Communication for Bayer in Southern Africa.
Applications are now open for intrepid self-starters with highly innovative digital health solutions. Interested applicants can now apply for either the Accelerator and Dealmaker programmes:
Accelerator Programme 2017
The Grants4Apps Accelerator is a mentoring programme for digital health startups which will be taking place in Berlin. This year up to five startups will be hosted in Berlin with the programme running from September until November. Entry into the programme offers health startups an opportunity to get mentoring by entrepreneurs and Bayer experts, office space for 100 days, and funding of 50,000€. Accelerator is open until 31 May 2017 for early stage startups.
Dealmaker Programme 2017
This programme calls for all mature teams, startups and companies that have a solution that is ready to go and could close a possible deal. Applications to Dealmaker will stay open until 30 June 2017.
Patel adds, “More than just another meaningless initiative, Grants4Apps is a clear opportunity and commitment to anchor our conversations in a territory which drives debate, involvement and meaning - providing scientific answers that are intended to help improve people’s lives.”
“There is real excitement about the new opportunities that this year’s programme will create for the successful startups. We have been encouraged by the responses received in previous calls for applications and would like to encourage all the innovative health startups in South Africa to visit www.grants4apps.com/berlin to take advantage of this opportunity as they stand a chance to have their work showcased on a global scale.” she concludes.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.co.za
Head of Communications, Southern Africa
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.